Work

Supplementary Figure S2 from Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies

Year: 2024

Type: supplementary-materials

Abstract: Supplemental Figure 2. Design of the SYNB1891 Phase 1 study.

DOI: 10.1158/1078-0432.27031621.v1

Authors: Jason J. Luke, Sarina A. Piha-Paul, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James F. Strauss, David L. Hava, Filip Janku

Language: English

Topic: Bacterial Cancer Therapy

Subfield: Biotechnology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4402804530

Cites:

Cited by:

Related to: